Search Results

Press Releases

Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024

October 28, 2024

·

1 min read

Genetown

CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001

CAMP4 Therapeutics Corp. today announced that the first participant has been dosed in the company’s Phase 1 clinical study of CMP-CPS-001, a potential first-in-class therapeutic for the treatment of urea cycle disorders (UCDs).

March 21, 2024

·

3 min read

Press Releases

CAMP4 Therapeutics Secures Orphan Drug Designation for CMP-CPS-001 for the Treatment of Urea Cycle Disorders

September 18, 2024

·

2 min read

Press Releases

CAMP4 Therapeutics Secures Rare Pediatric Disease Designation for CMP-CPS-001 for the Treatment of Urea Cycle Disorders

August 27, 2024

·

3 min read

Deals

Calibre Scientific Acquires CPS Analitica, a Provider of Chromatography Consumables in Italy

Calibre Scientific is pleased to announce the acquisition of C.P.S. Analitica S.r.l., an Italian provider of chromatography consumables for the pharmaceutical, biotech, life sciences, academic, food & beverage, environmental and chemical industries.

October 30, 2023

·

2 min read

Biotech Beach

CalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP)

CalciMedica Inc. today announced the publication of preclinical data in TheJournal of Clinical Investigation (JCI) Insight that details the potential benefit of CRAC channel inhibitors for chronic pancreatitis (CP).

June 6, 2023

·

5 min read

Biotech Beach

SpineX Receives NIH SBIR Phase II Award for SCiP Clinical Trial in Children With CP

SpineX Inc., a clinical stage bioelectric medtech company, is pleased to announce receipt of funding from the National Institutes of Health (NIH) through the Small Business Innovation Research Awards (SBIR).

September 26, 2023

·

2 min read

Drug Development

Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets

Finch Therapeutics Group, Inc. (the “Company,” “Finch,” or “Finch Therapeutics”) (Nasdaq: FNCH) today announced its decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) and focus on realizing the value of its intellectual property estate and other assets.

January 24, 2023

·

5 min read

Press Releases

Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

October 8, 2024

·

5 min read

Policy

Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND

Finch Therapeutics Group, Inc. announced that the U.S. Food and Drug Administration has removed the clinical hold on Finch’s investigational new drug application for CP101.

April 28, 2022

·

5 min read